Extramedullary plasmacytoma of the testis: A case report

Shimokihara, Kota; Kawahara, Takashi; Chiba, Sawako; Takamoto, Daiji; Yao, Masahiro; Uemura, Hiroji

doi:10.1016/j.eucr.2017.11.007

Cited by 10 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A trend towards an increase in triglyceride concentrations in the plasma of patients with EMM was also identified. Several EMM case studies have reported hyperlipidaemia, which is more predominant in patients with IgA myeloma [70][71][72]. MM patients with the IgA monoclonal protein type are also at higher risk of future EMM development [73].…”

Section: Discussionmentioning

confidence: 99%

Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures

Dunphy

Bazou

Henry

et al. 2023

Cancers

View full text Add to dashboard Cite

Multiple myeloma (MM) is an incurable haematological malignancy of plasma cells in the bone marrow. In rare cases, an aggressive form of MM called extramedullary multiple myeloma (EMM) develops, where myeloma cells enter the bloodstream and colonise distal organs or soft tissues. This variant is associated with refractoriness to conventional therapies and a short overall survival. The molecular mechanisms associated with EMM are not yet fully understood. Here, we analysed the proteome of bone marrow mononuclear cells and blood plasma from eight patients (one serial sample) with EMM and eight patients without extramedullary spread. The patients with EMM had a significantly reduced overall survival with a median survival of 19 months. Label-free mass spectrometry revealed 225 proteins with a significant differential abundance between bone marrow mononuclear cells (BMNCs) isolated from patients with MM and EMM. This plasma proteomics analysis identified 22 proteins with a significant differential abundance. Three proteins, namely vascular cell adhesion molecule 1 (VCAM1), pigment epithelium derived factor (PEDF), and hepatocyte growth factor activator (HGFA), were verified as the promising markers of EMM, with the combined protein panel showing excellent accuracy in distinguishing EMM patients from MM patients. Metabolomic analysis revealed a distinct metabolite signature in EMM patient plasma compared to MM patient plasma. The results provide much needed insight into the phenotypic profile of EMM and in identifying promising plasma-derived markers of EMM that may inform novel drug development strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures

Dunphy

Bazou

Henry

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…In cases involving multiple tumor lesions, systemic chemotherapy or monoclonal antibodies are usually indicated. [7,8] Daratumumab is a human IgG kappa monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma cells, and induces direct and indirect antimyeloma activity. [9] It is used from the third line or more of treatment in progressive multiple myeloma, when prior therapy included a proteasome inhibitor and an immunomodulatory drug.…”

Section: Discussionmentioning

confidence: 99%

Testicular Plasmacytoma

Sevilla¹,

Herrando²,

Pallàs³

et al. 2021

Clinic Res Urol

View full text Add to dashboard Cite

e present a 75-year-old male patient with the following medical history: Bilateral inguinal herniorrhaphy, hypertension, gastroesophageal reflux, and Stage III-A immunoglobulin G (IgG) kappa multiple myeloma with advanced bone disease. He attended the urology hospital consultation by request from Primary Healthcare Unit due to an increase in the size of the right testicle for 1 month.Physical examination revealed right scrotum with double size of the left, hard consistency testis with no pain on palpation, and normal left testicle. The patient had not had fever or previous trauma and neither had associated voiding symptoms.Testicular ultrasound reported the presence of a normal left testicle, heterogeneous 35 × 22 × 52 mm right testis with decreased echogenicity, increased vascularization, no nodular lesions, and more hypoechoic and vascularized solid area that was located in the most caudal part of the testicle and surrounded it laterally, being about 55 mm thick. Both of the epididymis were normal and mild bilateral hydrocele was observed.With the diagnostic of testicular tumor, blood tests were performed with tumor markers that were within normality (alpha-fetoprotein 0.72 IU/ml and beta-human chorionic gonadotropin 2 IU/l). The thoracoabdominal computed tomography scan showed the absence of extratesticular disease and the presence of multiple bone involvement in relation to his history of multiple myeloma.With a correct preoperative study, a right inguinal orchiectomy was performed. The patient was discharged after 24 h.The pathological anatomy study revealed the following findings. The right orchiectomy specimen of 10 × 6 × 4.5 cm length and weighing 131.20 g [Figure 1]. On section, smoothwalled cystic tunica vaginalis was observed and testis was

show abstract

“…Rarely it can involve testes, bladder, orbit. 2,3,4,5 Previously one case of prostate involvement is reported along with systemic disease (active myeloma). 6 (a) Pre-treatment PET-CT ; Intensely FDG-Avid mass (shown by arrow) in the prostate gland extending into the bladder and into the left perineum (SUV max 16) (b) Post cycle 2 PET-CT scan; No FDG avid mass in the prostate As per Revised IMWG criteria, diagnosis of solitary extramedullary plasmacytoma requires biopsy proven solitary lesion of soft tissue with evidence of clonal plasma cells, a normal bone marrow with no evidence of plasma cells, no end organ damage (CRAB features) and no evidence of bony disease on imaging.…”

Section: Discussionmentioning

confidence: 99%

Solitary extramedullary plasmacytoma of prostate on the background of treated prostate adenocarcinoma

2020

IJCR

View full text Add to dashboard Cite

show abstract

Extramedullary plasmacytoma of the testis: A case report

Cited by 10 publications

References 4 publications

Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures

Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures

Testicular Plasmacytoma

Solitary extramedullary plasmacytoma of prostate on the background of treated prostate adenocarcinoma

Contact Info

Product

Resources

About